NCT00006082已完成2 期
Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On - 2 Days Off" Oral Treatment in Advanced Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC1 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2000年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have advanced small cell lung cancer.
详细描述
OBJECTIVES:
- Determine the objective response and duration of objective response in patients with advanced small cell lung cancer treated with nitrocamptothecin.
- Determine the probability of objective response as expressed by the response rate in patients treated with this regimen.
- Determine the toxicities of this regimen in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to disease status (sensitive vs refractory).
Patients receive oral nitrocamptothecin daily for 5 consecutive days each week for 3 weeks. Treatment continues every 3 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD) receive up to 4 additional courses past SD. Patients who achieve partial response (PR) or complete response (CR) receive a minimum of 2 additional courses past CR or PR.
Patients are followed every 6 weeks until disease progression or initiation of another antitumor treatment.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically proven advanced (extensive stage) small cell lung cancer with progressive or recurrent disease after 1 first line chemotherapy regimen
- •Sensitive disease, defined as a response to prior chemotherapy lasting at least 3 months from the end of all prior treatment, including radiotherapy, until the time of progression OR
- •Refractory disease, defined as no response to prior chemotherapy, or a response to prior chemotherapy followed by progression within 3 months after completion of all prior therapy, including radiotherapy
- •Minimum of 1 target lesion that can be accurately measured in at least 1 dimension
- •20 mm or more with conventional techniques OR
- •10 mm or more with spiral CT scans
- •No symptomatic brain metastases
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Life expectancy:
- •At least 3 months
- •Hematopoietic:
- •Neutrophil count at least 2,000/mm^3
- •Platelet count at least 100,000/mm^3
- •Bilirubin less than 1.5 times upper limit of normal (ULN)
- •Alkaline phosphatase, SGOT, and SGPT no greater than 2.5 time ULN (no greater than 5 times ULN if hepatic metastases present)
- •Creatinine no greater than 1.7 mg/dL
- •Cardiovascular:
- •No ischemic heart disease within the past 6 months
- •Normal 12 lead electrocardiogram
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
- •No other prior or concurrent malignancy except cone biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell skin cancer
- •No unstable systemic disease or active uncontrolled infection
- •No psychological, familial, sociological, or geographical condition that may preclude compliance
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Prior maintenance therapy with biologic agents following first line chemotherapy allowed
- •No concurrent filgrastim (G-CSF) with nitrocamptothecin
- •Chemotherapy:
- •See Disease Characteristics
- •Greater than 4 weeks since prior chemotherapy
- •No more than 1 prior chemotherapy regimen for extensive disease
- •Alternate or sequential use of different regimens without interruption in first line treatment is considered 1 first line therapy
- •Endocrine therapy:
- •Not specified
- •Radiotherapy:
- •See Disease Characteristics
- •Greater than 4 weeks since prior radiotherapy
- •Greater than 2 weeks since prior major surgery
- •No other concurrent anticancer therapy
- •No other concurrent investigational therapy
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary TractTransitional Cell Cancer of the Renal Pelvis and UreterUrethral CancerBladder CancerNCT00006026European Organisation for Research and Treatment of Cancer - EORTC21
已完成
2 期
Nitrocamptothecin in Treating Patients With Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00005826European Organisation for Research and Treatment of Cancer - EORTC17
已完成
2 期
Nitrocamptothecin in Treating Patients With Advanced Ovarian CancerOvarian CancerNCT00006230European Organisation for Research and Treatment of Cancer - EORTC51
已完成
2 期
Nitrocamptothecin in Treating Patients With Metastatic MelanomaMelanoma (Skin)NCT00005875Astex Pharmaceuticals, Inc.
Unknown
3 期
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic CancerPancreatic CancerNCT00005871Astex Pharmaceuticals, Inc.